SEC 13F Intelligence

Managers / Q1 2019 · view latest →

Aviva Holdings Ltd.

CIK 0001603935 · ALBANY FINANCIAL CENTER, SUITE 207, LEWIS DRIVE N7776, NEW PROVIDENCE, C5, 00000 · 407-909-9970

Reported Value
$456M
Q1 2019
Positions
9
Filings on Record
28
2019–present window
Filed
May 15, 2019
original filing

Summary

Aviva Holdings Ltd. reported $456M in U.S.-listed holdings across 9 positions for Q1 2019.

The portfolio is heavily concentrated: MRTXEUR alone accounts for 50.4% of reported value.

Compared with Q4 2018, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+1.0%
vs prior filed quarter
Largest Position
+50.4%
Mirati Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $317MQ4 ’18Q1 ’19: $456MQ2 ’19: $478MQ3 ’19: $370MQ3 ’19Q4 ’19: $669MQ1 ’20: $439MQ2 ’20: $643MQ2 ’20Q3 ’20: $767MQ4 ’20: $1.0BQ1 ’21: $752MQ1 ’21Q2 ’21: $724MQ3 ’21: $709MQ4 ’21: $615MQ4 ’21Q1 ’22: $379MQ2 ’22: $278MQ3 ’22: $277MQ3 ’22Q4 ’22: $174MQ1 ’23: $143MQ4 ’23: $13MQ4 ’23Q1 ’24: $13MQ2 ’24: $26MQ3 ’24: $41MQ3 ’24Q4 ’24: $21Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 97.0%US DOMESTIC: 3.0%Other: 0.0%
  • Common Stock · 97.0% · $442M
  • US DOMESTIC · 3.0% · $14M
  • Other · 0.0% · $106,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2018 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MGNXMACROGENICS INC.SOLD OUT−3.8K0−$48,000$0
ESPRESPERION THERAPEUTICS INC NEHELD−23.0K441.6K−$4M$18M
MRTXEURMIRATI THERAPEUTICS INCHELD+03.14M+$97M$230M
MDCOUSDMEDICINES COHELD+03.78M+$33M$106M
INSGEURINSEEGO CORPHELD+018.80M+$11M$89M
INSEEGO CORPHELD+013.70M+$2M$14M
SOLID BIOSCIENCES INC.HELD+011.5K−$202,000$106,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

5 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COMMON50.43%$230M3.14M
2MDCOUSDMEDICINES COhistory →COMMON23.17%$106M3.78M
3INSGEURINSEEGO CORPCOMMON · NOTE 5.500% 6/122.49%$102M32.50M
4ESPRESPERION THERAPEUTICS INC NEhistory →COMMON3.89%$18M441.6K
5SOLID BIOSCIENCES INC.COMMON0.02%$106,00011.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$21M1Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$41M2Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$26M2Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$13M2May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$13M2Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review5Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review5Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$143M5May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$174M5Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$277M6Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$278M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$379M7May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$615M7Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$709M7Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$724M6Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$752M4May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.0B4Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$767M4Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$643M6Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$439M5May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019REVEALED$669M6Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$370M6Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$478M6Aug 28, 2019RESTATEMENTchanges · EDGAR ↗
Q1 2019$456M9May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$317M10Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 2 additional managers.

  • Braslyn Ltd.28-17341
  • Avid Group Ltd.28-18582

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.